Want to invest in legalized marijuana but concerned about a DEA crackdown? What happens to wiretapping in Colorado may be an early clue of the feds' stance.
The party may soon be over for companies trying to dodge U.S. taxes through so-called inversions, a move that has become popular lately among drug firms.
They make for strange bedfellows, but Apple and IBM, which once competed in the personal computer era, are now teaming up in the digital age.
Stocks gain on Wall Street with broadcasting shares getting a big boost from the Supreme Court's decision against Aereo.
After a 40-year ban, a few companies have been given the green light to export unrefined oil, which could lead to higher gas prices in the U.S.
Wall Street takes a tiny breather after the Dow and S&P hit new records but more action in mergers and acquisitions helps keep things interesting.
Cialis maker Eli Lilly has struck a licensing deal allowing French drugmaker Sanofi to sell a nonprescription version of the pill in major markets.
The job prospects for this year's college grads have improved slightly, but they're starting their careers with more debt than any other class.
Merck said it would sell its consumer care business to Germany's Bayer for $14.2 billion.
Pfizer reports revenues well below Wall Street expectations, hurt by falling sales of generic medicines it calls established pharmaceuticals.
A huge merger may be brewing in the drug industry. Pfizer has approached British rival AstraZeneca about a takeover, according to the Sunday Times.
Excitement is starting to build over the planned American IPO of the Chinese e-commerce giant Alibaba. It could be the largest U.S. IPO ever.
After five straight quarters of strong gains, the market rode a treadmill for the past 3 months -- lots of movement, but ending up pretty much where it started.
Biotech and health care stocks looked like they needed a transfusion of market confidence Monday, as for the second session in a row, their performance was anemic.
Tensions over the Ukraine-Russian conflict remain high, but there were no new developments that blocked investors on Wall Street from buying.
Federal health experts are taking a second look this week at the heart safety of pain medications used by millions of Americans to treat arthritis and other aches and pains.
A proposed bill in one state could change future generations of smartphones that all of us buy.
The NFL has awarded a series of extra games for next season to CBS, but that means the network will have to find a temporary new home for one of its most popular sitcoms.
U.S. investors are uncertain about whether we're in the midst of a temporary retreat, or a more fundamental end to the long running bull market.
Liquor-maker Beam agrees to be acquired by Suntory Holdings of Japan for $16 billion.
GlaxoSmithKline will stop paying doctors for promoting its drugs and scrap prescription targets for its marketing staff.
CVS Caremark's third-quarter net income climbed 25 percent in a performance that beat Wall Street expectations.
Johnson & Johnson has agreed to pay a $2.2 billion penalty and plead guilty to a misdemeanor, ending federal investigations.